Floatz logo

FLUDEOXYGLUCOSE

Anal Basaloid Carcinoma

ECOG-ACRIN Cancer Research GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Anal Basaloid Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BB
Nivolumab
National Cancer Institute (NCI)
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
ECOG-ACRIN Cancer Research Group
Phase 2CCC
Capecitabine
ECOG-ACRIN Cancer Research Group
Phase 2CCC
FLUOROURACILUM
ECOG-ACRIN Cancer Research Group
Phase 2CCC
MITOMYCIN C
ECOG-ACRIN Cancer Research Group
Phase 2CCC

Same molecule, other indications

FLUDEOXYGLUCOSE is also rated in:

Recurrent Adult Brain TumorDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →